Peak health "Baibo into the enterprise" assessment ended
Release time:
2020-08-14
Peak Health "Baibo Entering Enterprise" Assessment Completed
News 10# August 25 On the afternoon of the 10th, Jiang Dejin, Deputy Minister of Organization Department and Director of Recruitment Bureau of Wucheng District Party Committee, Zhang Xiongwei, Deputy Director of Talent Office of District Party Committee Organization Department, Wang Xusheng, Deputy Director of Science and Technology Bureau, Zhang Yi, Chief of Industry Section, at Jianfeng Health Technology Company, the third batch of "Baibo Enterprise" assessment in 2018 was conducted. Dr. Pu Shoucheng of Zhejiang Normal University and Chen Daiyou, general manager of Jianfeng Health, and other relevant personnel participated in the assessment meeting.
Jianfeng Health signed a contract with Dr. Pu Shoucheng of Zhejiang Normal University in , 2016 , , . Dr. Pu entered Jianfeng Health Technology and was mainly responsible for the research and development of innovative Chinese herbal pieces and the exploration of plant extraction technology in the research and development center, and assisted in the research and development project and application of health food. At the meeting, Dr. Pu first summarized the work of 2 years in-depth peak health. He mainly carried out the experimental design of "Research on Purification Process of Hypoglycemic Active Component D Pinol in Cornbean Extract"; Establishment of detection method for D Pinol content in carob extract; 2 organized company personnel to visit the school for exchange and docking, use the public platform of the school to complete other projects for the company; Organize the staff of the research and development department and the quality department to conduct "research on the development of functional health products" and "application analysis of LCMS " learning lectures 2 times; through the freeze dryer and mass spectrometry laboratory of the school's most important platform, the "experiment of freeze-drying gastroma tablets" and "LCMS identification and analysis experiment of Ophiopogonis acid in Pinellia ternata" 2 times were completed. And promote the inclusion of peak health into the list of shared enterprises in the virtual simulation laboratory of biotechnology in Zhejiang Normal University; during the period, the patent specification "method for purifying D- pinitol from carob aqueous extract" was also drafted.
Chen Daiyou, on behalf of Jianfeng Health, evaluated and fully affirmed Dr. Pu 2 years of work. Yang Hao, manager of the research and development department, also summarized Dr. Pu's work in the technical field. Jiang Dejin and his party inquired about the details of the project, introduced the talent policy of the municipal government, and put forward relevant opinions and suggestions.
Chen Daiyou said that the introduction of doctoral talents has solved the demand of enterprises for high-quality talents, further enriched the scientific research team and improved the research and development capability of enterprises. Peak Health has submitted the recommendation form for doctoral candidates to enter enterprises in 2018 and the solicitation form for enterprises to introduce doctoral candidates in 2019 , in the future, doctoral talents in analysis, detection and biotechnology will be introduced to help Jianfeng Health improve relevant detection methods and improve the development and utilization of functional ingredients of traditional Chinese medicine and plant extracts. (Xu Feng)
News Link:
"Hundred Doctors Entering Enterprises Plan" is referred to as "Baibo Entering Enterprises". It is the leading group of talents work of Jinhua Municipal Committee of the Communist Party of China to implement the innovation-driven development strategy of Jinhua Municipal Committee, further promote the cooperation of industry-university-research alliance, and promote the sharing of human resources and scientific research results between universities and institutions and local enterprises, serve the local economic and social development, promote the government, enterprises, universities, talents win-win and start the implementation. It is planned to spend years to arrange 20 doctors and professors from colleges and universities (mainly in Zhejiang undergraduate colleges and universities) to take up temporary posts in Jinhua high-tech enterprises as research and development leaders, with a term of office of . The positions are generally assistant to the president (director) of the enterprise research institute (research and development center, technology center). Through doctors and professors to carry out scientific research activities on the front line of enterprises, we can speed up the production and transformation of scientific research achievements of colleges and universities in Jinhua City, promote the tackling of technical problems of enterprises, and promote the establishment of closer cooperation between universities and enterprises and the sharing mechanism of scientific and technological achievements. The relevant municipal departments will organize the annual assessment of the scientific research activities and achievements of the temporary staff every year, and the municipal finance will bear the reward funds for the temporary staff, while the enterprises that receive the temporary staff will be given priority to the support of technical transformation, science and technology, talents and other projects.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page